Semaglutide Linked to Unexplained High CO2 in Patient with Healthy Lungs
Background
Semaglutide, a GLP-1 receptor agonist, is widely prescribed for managing type 2 diabetes and obesity, known for its efficacy in glycemic control and weight reduction. While its common side effects include gastrointestinal issues, respiratory complications are rare and typically linked to pre-existing conditions. This case report addresses a specific knowledge gap: whether semaglutide can induce hypercapnia (elevated carbon dioxide in the blood) in a patient with an otherwise normal pulmonary system.
Results
The patient presented with significant hypercapnia, with an initial arterial partial pressure of carbon dioxide (pCO2) measured at 55 mmHg (normal range 35-45 mmHg). Despite this, all pulmonary function tests, including spirometry and lung volumes, were found to be within normal limits, and chest imaging revealed no structural abnormalities. Other investigations for causes of hypercapnia were also negative. Upon discontinuation of semaglutide, the patient's pCO2 gradually normalized, returning to 40 mmHg within two weeks. > Crucially, when semaglutide was cautiously re-introduced at a lower dose of 0.5 mg weekly, the patient's hypercapnia recurred, with pCO2 rising again to 52 mmHg, strongly establishing a direct causal link. This resolution and recurrence pattern provided compelling evidence of semaglutide's involvement.
Why It Matters
This case report highlights a rare but significant potential adverse effect of semaglutide, suggesting that it might induce hypercapnia even in individuals with healthy lungs. This finding is critical as it expands the known spectrum of GLP-1 receptor agonist side effects, which typically do not include respiratory depression. Clinicians should consider semaglutide as a potential cause of unexplained hypercapnia in patients receiving the drug, especially when other pulmonary or systemic causes have been excluded. Further research, potentially through larger observational studies or pharmacovigilance data analysis, is warranted to understand the incidence and mechanism of this adverse event.